Welcome to our dedicated page for Cbdmd news (Ticker: YCBD), a resource for investors and traders seeking the latest updates and insights on Cbdmd stock.
cbdMD, Inc. (YCBD) provides premium hemp-derived CBD products and functional mushroom supplements through brands like cbdMD, Paw CBD, and ATRx Labs. This news hub offers investors and industry observers centralized access to official updates from this innovative wellness company.
Track all regulatory developments, product launches, and financial disclosures through verified press releases and third-party analysis. Our curated collection helps stakeholders monitor key areas including cannabinoid research advancements, retail distribution expansions, and THC-free product innovations across human and pet wellness markets.
Discover timely updates on earnings reports, manufacturing compliance updates, and strategic partnerships that shape cbdMD's position in the competitive CBD sector. Content is organized for quick scanning while maintaining depth for professional analysis needs.
Bookmark this page for ongoing insights into how YCBD navigates regulatory challenges and capitalizes on emerging trends in functional health. Check regularly for new developments affecting this vertically integrated producer of science-backed wellness solutions.
Herbal Oasis has achieved significant recognition at the 2025 High Spirits Awards, securing multiple medals for their hemp-infused beverages. Their products earned a Gold Medal for Mango Bliss, Silver Medals for Lemon Lift and Tropical Twist, and a Bronze Medal for Berry Fusion.
Launched in late 2024, the brand competes in the 'Other Infused Beverage Products' category, offering non-alcoholic alternatives combining hemp-derived THC, CBG, and functional mushrooms. The recognition comes just four months after their national launch.
The market outlook appears promising, with Euromonitor International projecting hemp-derived THC beverage sales to reach $4.1 billion by 2028. The company has begun distribution in Alabama, Florida, and North Carolina, with plans for expansion throughout spring and summer, while also offering nationwide delivery through their website.
cbdMD (YCBD) has announced two significant corporate actions effective May 6, 2025: the automatic conversion of its 8% Series A Cumulative Convertible Preferred Stock into Common Stock, and a one-for-eight reverse stock split.
The preferred stock conversion will convert each preferred share into thirteen common shares, eliminating approximately $6.7 million in accrued dividend liabilities and $4.0 million in perpetual annual obligations. The last trading day for preferred stock will be May 5, 2025.
Following both corporate actions, YCBD's outstanding common shares will consolidate from approximately 71.26 million to 8.91 million shares. The reverse split will be effective after market close on May 6, 2025, with post-split trading beginning May 7, 2025. The company will maintain its NYSE American listing under the YCBD symbol with a new CUSIP number.
cbdMD (NYSE: YCBD) announced shareholder approval for the automatic conversion of its Series A Preferred Stock into Common Stock at its April 10, 2025 annual meeting. The conversion will transform each preferred share into thirteen common shares, eliminating approximately $6.7 million in accrued dividend payments and $4 million in annual dividend obligations.
The company also secured shareholder approval for:
- Election of seven directors for the 2026 term
- Appointment of Cherry Bekaert LLP as independent auditor
- Authorization for a potential reverse stock split ranging from 1:3 to 1:10 within one year
CEO Ronan Kennedy stated this conversion will enhance their capital structure, enable reinvestment in growth initiatives, and support continued NYSE American listing requirements while removing barriers to strategic M&A activities.
Herbal Oasis, a hemp-derived THC-infused social seltzer brand, has announced its distribution expansion into Alabama and select Florida Panhandle markets starting late March 2025. The alcohol-free beverage, owned by cbdMD, combines hemp-derived THC, CBG, and functional mushrooms.
Each 12-ounce can features:
- Hemp-Derived Delta-9 THC + CBG
- 2,500mg of functional mushrooms (Lion's Mane, Reishi, Cordyceps)
- Nano-liposomal technology for 10-15 minute onset
The product will be available across major Alabama cities and Florida Panhandle locations through grocery chains, convenience stores, wellness shops, and hospitality venues. According to Euromonitor International, hemp-derived THC beverage sales doubled in 2024 and are projected to reach $4.1 billion by 2028, representing a 1,600% increase from $239 million in 2023.
cbdMD (NYSE: YCBD) has reached a significant milestone in its UK regulatory journey as its Novel Food dossier (RP793) advances to the final phase of assessment with the UK Food Standards Agency (FSA). The company's proprietary CBD isolate, with over 97% purity, received a positive safety assessment on February 28, 2025.
The FSA's evaluation confirms that cbdMD's ingredient meets UK food safety standards, is free from contaminants and controlled cannabinoids like THC, and supports safe consumption levels for adults. The company initiated this process in March 2021 and became the first U.S. brand to receive dossier validation in February 2022.
This development positions cbdMD among the few companies approaching full Novel Food authorization in the UK's £800 million CBD market. The achievement is expected to enhance consumer confidence and expand market share in the regulated CBD industry.
cbdMD (NYSE: YCBD) reported financial results for Q1 FY2025 ended December 31, 2024. The company achieved $5.1 million in revenue, marking a 12% sequential increase from Q4 FY2024, though representing a 19.1% year-over-year decrease. Notable achievements include the company's first-ever positive non-GAAP Adjusted EBITDA of $214,000 and a net income of $15,000, improving by approximately $1 million from the prior year.
The company maintained a 66% gross profit margin and reduced its operating loss to $80,000 from $1.1 million in the previous year. Direct-to-consumer sales accounted for 77% of total revenue at $4.0 million, while wholesale revenue increased by 22% to $1.1 million. The company ended the quarter with $2.0 million in cash and became debt-free following the conversion of remaining convertible notes in January 2025.
cbdMD also launched Herbal Oasis, a new ready-to-drink hemp-derived beverage brand, and announced plans for its 2025 annual meeting, including a proposal to convert Series A Preferred stock and accrued dividends into common stock.
cbdMD (NYSE American: YCBD) has announced it will host a conference call on Thursday, February 13, 2025, at 4:20 p.m. Eastern Time to discuss the company's financial results for the first quarter of fiscal year 2025, ended December 31, 2024, and business progress.
The conference call will be accessible via multiple channels, including USA/Canada toll-free number (844-763-8274) and International number (647-484-8814). A replay will be available through USA/Canada (855-669-9658) and International (412-317-0088) numbers using passcode 7970691. Additionally, a webcast replay will be accessible through March 13, 2026.
cbdMD (NYSE American: YCBD) has announced the full satisfaction of its Senior Secured Convertible Notes through conversion into common stock. As of January 14, 2025, the company has 6,262,833 shares of common stock outstanding. The conversion, completed ahead of maturity, has strengthened the company's financial position and enhanced cash reserves.
CEO & CFO Ronan Kennedy highlighted that the Notes provided essential working capital over the past year, and their conversion has left the company debt-free, excluding normal operational accounts payable. This development provides greater flexibility for capital allocation toward profitable revenue growth.
cbdMD is known for its THC-free CBD products, including the cbdMD, Paw CBD, and ATRx Labs brands, offering various products from CBD tinctures and gummies to pet products and functional mushroom supplements.
cbdMD (NYSE American: YCBD) has announced significant debt reduction through conversions of its Senior Secured Convertible Notes. The outstanding principal amount has been reduced to approximately $56,000 as of January 8, 2025, following conversions that resulted in the issuance of 609,717 shares of common stock. The conversions reduced the principal by about $309,000 plus accrued interest.
The company reported having $2.1 million in cash and cash equivalents at the end of the first fiscal quarter, with a total of 6,152,841 shares of common stock outstanding as of January 8, 2024. CEO & CFO Ronan Kennedy highlighted improved balance sheet conditions and favorable liquidity position entering calendar 2025.
cbdMD (NYSE American: YCBD) has received a notice of noncompliance from NYSE American dated December 31, 2024, for failing to maintain stockholders' equity of $2 million or more. The company reported stockholders' equity of $1,963,417 as of September 30, 2024, and losses in four of its five most recent fiscal years.
The company remains under a previously accepted compliance plan from August 20, 2024, addressing noncompliance with the $4 million stockholders' equity requirement. cbdMD must regain compliance by December 5, 2025, or face potential delisting. During this period, both common stock (YCBD) and preferred stock (YCBD-PA) will continue trading with a 'BC' (below compliance) designation.
The company has reduced cash consumption from $4.9 million in fiscal 2023 to approximately $0.7 million in fiscal 2024. To achieve compliance, cbdMD is considering converting preferred stock and its accrued dividend ($4.67 million as of September 30, 2024) into common stock, subject to shareholder approval.
